Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: Results from NCI-MATCH (EAY131)
    Journal Article

    Johnson, D. B.; Zhao, F.; Noel, M.; Riely, G. J.; Mitchell, E. P.; Wright, J. J.; Chen, H. X.; Gray, R. J.; Li, S.; McShane, L. M.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations
    Journal Article

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed stage IV squamous cell lung cancers
    Journal Article

    Paik, P. K.; Kim, R. K.; Ahn, L.; Plodkowski, A. J.; Ni, A.; Donoghue, M. T. A.; Jonsson, P.; Villalona-Calero, M.; Ng, K.; McFarland, D.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • The Human Tumor Atlas Network: Charting tumor transitions across space and time at single-cell resolution
    Editorial

    Rozenblatt-Rosen, O.; Regev, A.; Oberdoerffer, P.; Nawy, T.; Hupalowska, A.; Rood, J. E.; Ashenberg, O.; Cerami, E.; Coffey, R. J.; Demir, E.; more...
    Cell (2020)

    Fulltext@MSK | Save
  • Acquired resistance to immune checkpoint inhibitors
    Review

    Schoenfeld, A. J.; Hellmann, M. D.
    Cancer Cell (2020)

    Fulltext@MSK | Save
  • Nivolumab (N) plus low-dose ipilimumab (I) vs platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Checkmate 227 part 1 final analysis
    Meeting Abstract

    Reck, M.; Peters, S.; Ramalingam, S.; Paz-Ares, L.; Caro, R. B.; Zurawski, B.; Kim, S. W.; Alexandru, A.; Lupinacci, L.; Jitnenez, E. D.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with NTRK fusion-positive solid tumors or ROS1-positive NSCLC with CNS metastases
    Meeting Abstract

    Paz-Ares, L.; Dziadziuszko, R.; Drilon, A.; John, T.; Krebs, M.; Demetri, G.; Shaw, A. T.; Siena, S.; Wolf, J.; Farago, A. F.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Entrectinib in locally advanced / metastatic ROS1 and NTRK fusion-positive (NTRK plus ) non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    Springfeld, C.; de Braude, F.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B.; Huang, X.; Pitcher, B.; Doebele, R. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Genomic landscape of entrectinib resistance from circulating tumor DNA (CTDNA) analysis in STARTRK-2
    Meeting Abstract

    Doebele, R. C.; Dziadziuszko, R.; Drilon, A.; Shaw, A. T.; Wolf, J.; Farago, A. F.; Dennis, L.; Riehl, T.; Simmons, B.; Wu, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
    Meeting Abstract

    Leyvraz, S.; Hyman, D. M.; van Tilburg, C. M.; Albert, C. M.; Tan, D. S.; Geoerger, B.; Farago, A. F.; Laetsch, T. W.; Kummar, S.; Doz, F.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save